Financings Of The Fortnight: Notable Uptick In Series A Rounds So Far In 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
A strong second half of 2013 could mean a pace of start-up formation not seen since before 2007-2008. Plus news on recent financings by Prosensa, MannKind, OncoEthix and Cardio3 Biosciences.
You may also be interested in...
Epigenetic Modifiers Take Center Stage, Big Pharma Takes Notice
Epigenetic modifiers are targeting a widening range of indications as growing knowledge of the underlying biology enables improved agents and therapeutic strategies. Nonetheless, issues of selectivity, toxicity, and finding adequate biomarkers still prevent the field from reaching its full potential.
Deals in Depth: February 2024
Just one $1bn+ alliance was penned in February, compared to ten in the previous month. In the top alliance by deal value, Neomorph and Novo Nordisk entered into a potential $1.46bn agreement for the discovery, development, and commercialization of molecular glue degraders (MGDs) for cardiometabolic and rare diseases. The collaboration brings together Novo Nordisk's expertise in those disease areas with Neomorph's MGD discovery platform. Neomorph will lead discovery and preclinical activities against selected targets with Novo Nordisk having the right to exclusively pursue further clinical development and commercialization of the compounds.
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.